Answers are grounded in this paper and cite their sources.
We report the acute onset of aseptic sinusitis in 2 patients receiving the immune checkpoint inhibitors, ipilimumab and nivolumab, for treatment of metastatic melanoma. Ipilimumab, a monoclonal antibody targeting cytotoxic T-lymphocyte antigen-4, and nivolumab, targeting programmed cell death-1, have been associated with numerous immune-related adverse events. To the authors' knowledge, this is the first report of aseptic sinusitis as a consequence of immune checkpoint inhibition therapy.
No takes yet. Share an insight, caveat, or question.
Dein et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: